ArticleEuropean urology open science2023
Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.Nature medicine · 2025Trial
- Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [BMC cancer · 2026Observational
- Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026Article
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Circulating tumour DNA in mCRPC: bridging tumour biology and real-time treatment monitoring.Frontiers in molecular medicine · 2026Review
- Real-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland.Acta oncologica (Stockholm, Sweden) · 2025Observational
- Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis.European journal of nuclear medicine and molecular imaging · 2025Article
- Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management.Cancers · 2025Review
- Review
- Study of predictive factors for response toFrontiers in medicine · 2025Article
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.International journal of molecular sciences · 2025Review
- Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.Frontiers in oncology · 2025Review
- Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.Nature reviews. Urology · 2025Review
- Article
- Initial Experience with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response toJCO precision oncology · 2024Article
- Impact ofTheranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lutetium-177 prostate-specific membrane antigen radioligands ( Patient summary: We examined cell-free DNA in blood samples from patients with advanced metastatic prostate cancer who started treatment with lutetium-177-PSMA, a new radioligand therapy. We found that patients with genetic alterations in the androgen receptor gene or PI3K pathway genes did not experience a lasting benefit from lutetium-177-PSMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.